The ultimate goal of LiverScreen is to reduce mortality and morbidity from liver disease. The aim is to set up a targeted, easy-to-use, cost-beneficial screening program for detection of liver fibrosis in high-risk groups within the general population, using transient elastography as screening tool.
The Liverscreen project will screen a total of 30.000 people recruited from different european countries. FLASH will screen 3,500 patients for liver disease. By analysing the results from the 30.000 subjects recruited, the Liverscreen consortium can validate the diagnostic accuracy, cost-effectiveness and acceptability of using the TE technology to case-find advanced liver fibrosis in the general population. Moreover, LiverScreen will assess the prevalence of liver fibrosis within certain subpopulations based on health risk factors and will use this knowledge to fine-tune the case-finding. At project completion, the aim is to have a targeted, population-based screening intervention program for chronic liver diseases in Europe, ready for implementation.
LiverScreen has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 847989.
